Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.35 |
| ▸ | LOX | P28300 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097113 | 1.00 | RAB9A (0.41) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL5097179 | 0.85 | NPC1 (0.51) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL5097505 | 0.85 | NPC1 (0.51) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL5091015 | 0.84 | PDK2 (0.45) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL5091014 | 0.84 | PDK2 (0.45) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL5103249 | 0.83 | KMT2A (0.42) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL5103251 | 0.83 | KMT2A (0.42) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL4504977 | 0.80 | PDK2 (0.43) | RAB9ANPC1PDK2KMT2AROCK2 | |
| SCHEMBL5103233 | 0.79 | SIGMAR1 (0.46) | CCR1 | |
| SCHEMBL27706481 | 0.79 | RAB9A (0.46) | RAB9ANPC1PDK2KMT2AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | claimed |
| EP-1836196-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | claimed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| EP-1836196-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | RAB9A 2741/4885NPC1 1561/4885PDK2 4153/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | RAB9A 2741/4885NPC1 1561/4885PDK2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.